188 related articles for article (PubMed ID: 27824923)
21. Comparing the prognostic value of risk stratifying models for patients with lower-risk myelodysplastic syndromes: Is one model better?
Zeidan AM; Sekeres MA; Wang XF; Al Ali N; Garcia-Manero G; Steensma DP; Roboz G; Barnard J; Padron E; DeZern A; Maciejewski JP; List AF; Komrokji RS;
Am J Hematol; 2015 Nov; 90(11):1036-40. PubMed ID: 26284571
[TBL] [Abstract][Full Text] [Related]
22. Response to hypomethylating agents improves long-term outcomes for lower-risk patients with myelodysplastic syndrome in case-matched cohorts.
Baek DW; Lee YJ; Kim H; Ahn SY; Ahn JS; Shin HJ; Lee WS; Lee SM; Song IC; Lee HS; Park SW; Choi Y; Cho YY; Bae SH; Kim HJ; Sohn SK; Moon JH
Ann Hematol; 2018 Dec; 97(12):2309-2317. PubMed ID: 30073392
[TBL] [Abstract][Full Text] [Related]
23. Phase 2 study of low-dose clofarabine plus cytarabine for patients with higher-risk myelodysplastic syndrome who have relapsed or are refractory to hypomethylating agents.
Jabbour E; Faderl S; Sasaki K; Kadia T; Daver N; Pemmaraju N; Patel K; Khoury JD; Bueso-Ramos C; Bohannan Z; Ravandi F; Borthakur G; Verstovsek S; Miller D; Maduike R; Hosing C; Kantarjian HM; Garcia-Manero G
Cancer; 2017 Feb; 123(4):629-637. PubMed ID: 27741352
[TBL] [Abstract][Full Text] [Related]
24. [Scoring analysis on prognosis of 63 patients with melodysplastic syndrome].
Wei J; Chen Y
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2008 Apr; 16(2):305-11. PubMed ID: 18426654
[TBL] [Abstract][Full Text] [Related]
25. Favorable Outcomes With Tumor Burden Reduction Following Administration of Hypomethylating Agents Before Allogeneic Hematopoietic Cell Transplantation in Patients With Higher Risk Myelodysplastic Syndrome.
Park S; Baek DW; Sohn SK; Ahn JS; Kim HJ; Shin HJ; Chung JS; Lee SM; Lee WS; Lim SN; Lee YJ; Choi Y; Lee HS; Cho YY; Lee GW; Moon JH
Clin Lymphoma Myeloma Leuk; 2019 Jul; 19(7):e367-e373. PubMed ID: 31060990
[TBL] [Abstract][Full Text] [Related]
26. Utility of 5-Methylcytosine Immunohistochemical Staining to Assess Global DNA Methylation and Its Prognostic Impact in MDS Patients.
Chandra D; Tyagi S; Singh J; Deka R; Manivannan P; Mishra P; Pati HP; Saxena R
Asian Pac J Cancer Prev; 2017 Dec; 18(12):3307-3313. PubMed ID: 29286224
[TBL] [Abstract][Full Text] [Related]
27. Validation of the MD Anderson Prognostic Risk Model for patients with myelodysplastic syndrome.
Komrokji RS; Corrales-Yepez M; Al Ali N; Kharfan-Dabaja M; Padron E; Fields T; Lancet JE; List AF
Cancer; 2012 May; 118(10):2659-64. PubMed ID: 21956402
[TBL] [Abstract][Full Text] [Related]
28. Is International Prognostic Scoring System (IPSS) still standard in predicting prognosis in patients with myelodysplastic syndrome? External validation of the WHO Classification-Based Prognostic Scoring System (WPSS) and comparison with IPSS.
Park MJ; Kim HJ; Kim SH; Kim DH; Kim SJ; Jang JH; Kim K; Kim WS; Jung CW
Eur J Haematol; 2008 Nov; 81(5):364-73. PubMed ID: 18637029
[TBL] [Abstract][Full Text] [Related]
29. Validation of the Revised International Prognostic Scoring System for patients with myelodysplastic syndromes.
Savic A; Marisavljevic D; Kvrgic V; Stanisavljevic N
Acta Haematol; 2014; 131(4):231-8. PubMed ID: 24335346
[TBL] [Abstract][Full Text] [Related]
30. The myelodysplastic syndromes: analysis of prognostic factors and comparison of prognostic systems in 128 Chinese patients from a single institution.
Zhao WL; Xu L; Wu W; Yan H; Tang W; Hu J; Chen Y; Li JM; Zeng XY; Xiong SM; Shen ZX; Chen Z; Wang ZY; Chen SJ
Hematol J; 2002; 3(3):137-44. PubMed ID: 12111649
[TBL] [Abstract][Full Text] [Related]
31. Prognostic value of self-reported fatigue on overall survival in patients with myelodysplastic syndromes: a multicentre, prospective, observational, cohort study.
Efficace F; Gaidano G; Breccia M; Voso MT; Cottone F; Angelucci E; Caocci G; Stauder R; Selleslag D; Sprangers M; Platzbecker U; Ricco A; Sanpaolo G; Beyne-Rauzy O; Buccisano F; Palumbo GA; Bowen D; Nguyen K; Niscola P; Vignetti M; Mandelli F
Lancet Oncol; 2015 Nov; 16(15):1506-1514. PubMed ID: 26404501
[TBL] [Abstract][Full Text] [Related]
32. Hypomethylating Agent Therapy in Myelodysplastic Syndromes With Chromosome 3 Abnormalities.
Sallman DA; Barnard J; Al Ali NH; Garcia-Manero G; Sekeres MA; DeZern A; Steensma DP; Roboz G; Jabbour E; Maciejewski JP; Pierce S; Padron E; Lancet JE; Kantarjian H; List AF; Komrokji RS
Clin Lymphoma Myeloma Leuk; 2020 Sep; 20(9):e597-e605. PubMed ID: 32303488
[TBL] [Abstract][Full Text] [Related]
33. Incidence and prognostic significance of karyotype abnormalities in de novo primary myelodysplastic syndromes: a study on 331 patients from a single institution.
Bernasconi P; Klersy C; Boni M; Cavigliano PM; Calatroni S; Giardini I; Rocca B; Zappatore R; Caresana M; Quarna J; Lazzarino M; Bernasconi C
Leukemia; 2005 Aug; 19(8):1424-31. PubMed ID: 15920496
[TBL] [Abstract][Full Text] [Related]
34. Prognosis of patients with intermediate risk IPSS-R myelodysplastic syndrome indicates variable outcomes and need for models beyond IPSS-R.
Benton CB; Khan M; Sallman D; Nazha A; Nogueras González GM; Piao J; Ning J; Aung F; Al Ali N; Jabbour E; Kadia TM; Borthakur G; Ravandi F; Pierce S; Steensma D; DeZern A; Roboz G; Sekeres M; Andreeff M; Kantarjian H; Komrokji RS; Garcia-Manero G
Am J Hematol; 2018 Oct; 93(10):1245-1253. PubMed ID: 30051599
[TBL] [Abstract][Full Text] [Related]
35. [The application of a new prognostic score system for 435 cases of primary myelodysplastic syndrome diagnosed with WHO classification].
Wang XQ;
Zhonghua Nei Ke Za Zhi; 2009 Aug; 48(8):633-7. PubMed ID: 19954053
[TBL] [Abstract][Full Text] [Related]
36. Incorporation of mutations in five genes in the revised International Prognostic Scoring System can improve risk stratification in the patients with myelodysplastic syndrome.
Hou HA; Tsai CH; Lin CC; Chou WC; Kuo YY; Liu CY; Tseng MH; Peng YL; Liu MC; Liu CW; Liao XW; Lin LI; Yao M; Tang JL; Tien HF
Blood Cancer J; 2018 Apr; 8(4):39. PubMed ID: 29618722
[TBL] [Abstract][Full Text] [Related]
37. Identification of novel cytogenetic markers with prognostic significance in a series of 968 patients with primary myelodysplastic syndromes.
Solé F; Luño E; Sanzo C; Espinet B; Sanz GF; Cervera J; Calasanz MJ; Cigudosa JC; Millà F; Ribera JM; Bureo E; Marquez ML; Arranz E; Florensa L
Haematologica; 2005 Sep; 90(9):1168-78. PubMed ID: 16154839
[TBL] [Abstract][Full Text] [Related]
38. Validation of the revised International Prognostic Scoring System in treated patients with myelodysplastic syndromes.
Mishra A; Corrales-Yepez M; Ali NA; Kharfan-Dabaja M; Padron E; Zhang L; Epling-Burnette PK; Pinilla-Ibarz J; Lancet JE; List AF; Komrokji RS
Am J Hematol; 2013 Jul; 88(7):566-70. PubMed ID: 23605934
[TBL] [Abstract][Full Text] [Related]
39. Patient-related factors independently impact overall survival in patients with myelodysplastic syndromes: an MDS-CAN prospective study.
Buckstein R; Wells RA; Zhu N; Leitch HA; Nevill TJ; Yee KW; Leber B; Sabloff M; St Hilaire E; Kumar R; Geddes M; Shamy A; Storring J; Kew A; Elemary M; Levitt M; Lenis M; Mamedov A; Zhang L; Rockwood K; Alibhai SM
Br J Haematol; 2016 Jul; 174(1):88-101. PubMed ID: 26991631
[TBL] [Abstract][Full Text] [Related]
40. Balanced and unbalanced chromosomal translocations in myelodysplastic syndromes: clinical and prognostic significance.
Mohamed S; Latagliata R; Limongi MZ; Nigro S; Sangiorgi E; Nanni M; Piccioni A; Campagna A; Spiriti MAA; Carmosino I; Molica M; Mariggiò E; Rosati S; Colafigli G; Fazio F; Luca ML; Benedittis D; Scalzulli E; Breccia M; Mancini M
Leuk Lymphoma; 2020 Dec; 61(14):3476-3483. PubMed ID: 32870062
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
